The Nutritional and Biochemical Indicators of Cardiovascular and Chronic Kidney Diseases Patients Compared to a Normal Group

Mona A Mohamed 1, Amal H Emara 2; Nehad R Ibrahim 3; Entsar M. Ahmad 1
Fatma K Abd El-Hamid 2, *Hanaa H El-Sayed 2

1 Chemistry Department, Faculty of Science, Al-Azhar University, Cairo, Egypt
2 Nutritional Chemistry and Metabolism Department, National Nutrition Institute, Cairo, Egypt.
3 Clinical pathology, National Institute of Urology and Nephrology, Cairo, Egypt.

OUTLINE:

Chronic kidney disease (CKD) and cardiovascular disease (CVD) exacerbate each other's progression, increasing morbidity and mortality rates. Studying these interrelated conditions requires strict nutritional and biochemical monitoring. By comparing macro- and micronutrient intake to the recommended daily intake (RDI), biochemical tracking provides valuable information about metabolic diseases, aiding early diagnosis and tailored treatment regimens. This study involved 60 subjects: 30 healthy controls and 30 patients with CKD and CVD from the outpatient clinic of the National Institute of Urology and Nephrology in Cairo, Egypt. The findings demonstrated that macronutrient intake in both groups was lower than the RDI except for protein. Both groups had inadequate vitamin D (VD) intake, getting smaller than 50% of the RDI, with significant differences noticed in serum VD levels, which were less in the CKD+CVD group. Except for sodium intake, higher than the RDI in both groups, all mineral intakes were below the RDI, with magnesium and potassium intake less than 50% of the RDI. Biochemical markers of renal mission, except for the estimated Glomerular Filtration Rate (eGFR), were lower than normal in the patient group. The patient group had greater concentrations of cardiac markers such as creatine kinase, troponin, lactate dehydrogenase (LDH), and vascular cellular adhesion molecule-1 (VCAM-1). Their lipid profile showed significant increases in triglycerides, low-density lipoprotein (LDL-C), very LDL-C, atherogenic index (AI), and atherogenic coefficient (AC), while high-density lipoprotein (HDL-C) levels significantly decreased. This study emphasizes that nutritional intervention and novel biomarkers are crucial for these patients.

Keywords: Chronic Kidney and Cardiovascular Diseases patient – Nutrition – Biomarker
INTRODUCTION
The linked health disorders CKD and CVD provide major obstacles to the world's medical infrastructure. The coexistence of CKD and CVD exacerbates morbidity and mortality rates, necessitating vigilant surveillance strategies to manage patient outcomes effectively. Recent epidemiological data highlight the widespread prevalence and impact of these conditions, emphasizing the urgency for comprehensive care approaches. For instance, according to the study conducted by Mills et al (2015), Roughly 9.1% of people worldwide suffer from CKD, which greatly increases the incidence of chronic diseases globally. Simultaneously, CVD remains the leading cause of mortality globally, as evidenced by reports from the WHO in 2021; and GBD in 2020. These statistics underscore the critical need for targeted interventions and personalized care strategies in managing patients suffering from both CKD and CVD.

Nutritional and biochemical surveillance plays a crucial role in managing patients with CKD and CVD. Adequate nutritional status is critical, as malnutrition and imbalanced diets can exacerbate both kidney and cardiovascular dysfunction (Ikizler et al., 2021). Specifically, dietary focusing on sodium restriction, and protein intake, are critical for optimizing patient outcomes (Kim and Jung 2020); (Kalantar-Zadeh and Fouque 2017).

Studies by Kim and Jung (2020) and Mozaffarian and Others (2012) underscore the focal role of dietary factors in modulating the risk and progression of both CKD and CVD, highlighting the need for tailored nutritional strategies. Monitoring parameters such as protein intake, sodium restriction, and micronutrient status are essential in optimizing metabolic balance and cardiovascular health in this vulnerable population.

Biochemical observation is essential for the early detection of metabolic abnormalities and guiding therapeutic interventions in patients with CKD and CVD. Recent advancements in biomarker research have provided insights into the pathophysiological mechanisms underlying these diseases, enhancing physicians' ability to monitor disease progression and treatment response. Stopic et al. (2022) have identified novel biomarkers and biochemical pathways implicated in CKD and CVD, offering potential targets for prognostication and personalized management. Biomarkers that serum
creatinine, eGFR, lipid profiles, and inflammatory markers serve as valuable tools for risk stratification and therapeutic decision-making in this patient population. Integration of advanced biochemical assays and multi-omics approaches holds promise in refining risk assessment and tailoring precision medicine approaches for patients suffering from both CKD and CVD. Continued research and innovation in this field are essential to develop more effective monitoring techniques and therapeutic interventions, ultimately aiming to reduce morbidity.

**STUDY AIMED**

The research problem sought to address the following questions within the scope:
- How do the nutritional profiles of patients with CVD and CKD differ from those of individuals without these conditions?
- What are the biochemical indicators that exhibit significant variations between patients with CVD and CKD, and individuals with normal conditions?
- Are there specific biomarkers or biochemical parameters that serve as reliable indicators of the nutritional status in patients with CVD and CKD?

**SUBJECTS AND METHODS:**

For this study, sixty volunteers between the ages of 45 and 60 were selected from the National Institute of Urology and Nephrology's Department's outpatient clinic in Cairo, Egypt. Two categories were created from the cases: Group 1 (n=30) consisted of healthy individuals, a typical group. Group 2 (n = 30) patients with CVD and CKD. Age and sex are matched through two groups.

**Inclusion Criteria**

KDIGO (2012) guidelines should be followed for the screening and management of patients with CKD. The following was done using an eGFR to categorize CKD patients into stages 5: Stage 1: GFR > 90 mL/min, either normal or high. there are four phases of CKD: mild in the second phase (GFR = 60–89 mL/min), moderate in stage three (GFR = 30-59 mL/min), severe in the fourth stage (GFR = 15–29 mL/min), and end-stage in stage five (GFR≈ 15 mL/min). These are the same people who have been diagnosed with CVD based on electrocardiography (ECG) and blood cardiac enzyme levels, including troponin and CK-MB.
Exclusion Criteria:
This work excluded participants with malignancies, muscular problems, pancreatitis, diabetes mellitus, alcoholism, and smoking.

Dietary Evaluation:
The study participants were evaluated using a twenty-four-hour food recall. The energy and macro/micronutrient content of the 24-hour meal intake were determined using the food configuration tables published by NNI, (2006). The required daily intake (RDI) was compared to all nutrient content of food and beverages consumed, based on the conclusions of the joint Food and Drug Administration (FDA) expert opinion on human nutrient requirements (FDA, 2020).

Laboratory tests:
a) The equation declared by Levey and Else (2000) was used to calculate serum eGFR as follows:
Estimated GFR = 141 x min (S_Cr/K, 1)\(^a\) x max (S_Cr/K, 1)\(^1.209\) x 0.993\(^\text{Age}\) x 1.018 [if female] x 1.159 [if Black] S_Cr (standardized serum creatinine) = mg/dL., K = 0.7 (females) or 0.9 (males), \(a = -1.329\) (female) or -0.411 (male), Min = indicates the minimum of S_Cr/K or 1, max = indicates the maximum of S_Cr/K or 1, Age = Years

b) The colorimetric method of Trinder (1969) was applied to gauge serum total cholesterol; Bucolo and David (1973) used the same colorimetric technique to criterion serum triglycerides; Trinder (1969) used the same colorimetric analysis to estimate serum HDL-C level; de Cordova and de Cordova (2013) used the formula to calculate serum LDL-C as follows:
LDL- c (mg/dl) = TC- HDL-c – (TG/5)

c) Mougios, (2007) states that the Auto analyzer (BT1500) was utilized to estimate the creatinine kinase MB.
d) According to Giannitsis et al. (2010), the Cardiac Troponin was measured by a Cobas e411 analyzer (Roche, Germany). By Tietz et al., (1983), the auto-analyzer (BT1500) was used to estimate the cardiac lactate dehydrogenase.
e) ELISA was used to detect the serum levels of vascular adhesion molecule-1 (VCAM-1) (Nagel et al., 1994), vitamin DBP (Chun, 2012), and VD (1,25-Dihydroxy VD) (Holick et al., 2024).
f) The current equation was calculated as the atherogenic index (AI):
AI=[(log 10 [TG/HDL-c]) according to Nosrati et al. (2021). Another metric is the atherogenic coefficient (AC), which is deliberate by the equation
Analyzing Statistical Data:

The data was evaluated using the Statistical Package for the Social Sciences (SPSS, version 22). The descriptive mean ± standard error (SE) or standard deviation (SD) findings were obtained. A t-test paired two samples for means was used to analyze the data. According to Chan (2003), a difference was judged statistically big when $P$ was lower than 0.05.

Ethical considerations

The Scientific Research Morals Board confirmed the research of the General Authority for Hospitals and Educational Institutes under the reference number (IUN 00023).

FINDINGS AND DISCUSSION

Table (1) displays the distribution of the sample's criteria, CKD proteinuria stages, and dialysis between the two patient sets. In the normal group, there were more females and fewer meals than in the patient group. The patient group consisted of obese people (BMI = 30.8). In the patient group, stage 5 CKD had the largest percentage (46.7%), where 10% of group 2's urine contains traces of protein and 36.7% of them have positive proteinuria. On the other hand, 56.7% of G2 patients underwent dialysis.

Protein amount was consumed more than what was advised, while all macronutrient intake was below the RDI (Table 2). Group (2) (CKD and CVD) patients ingested more calories than the normal group. Patients in group 2 ate large amounts of protein. However, consumption of fat and fiber remained unchanged. It is advised to consume 25–35 kcal/kg of calories per day to maintain a neutral or positive nitrogen balance and to offset the increased energy expenditure that occurs during rest because of comorbidities and inflammation (Chan et al., 2017).

Remarkably, patients in group 2 consumed more calories than the normal group. The conventional wisdom that patients should maintain and enhance their nutritional status while unwell may contribute to this in part. Some have hypothesized that patients who are overweight or obese may receive better and more frequent care in addition to leading healthier lives than patients with other conditions (Wang et al., 2019). However, consuming large amounts of carbs may also be the cause of this elevated calorie value. It greatly improved by cutting back on the amount of carbohydrates consumed after being conscious of nutrition. Since extra calories are retained as fat,
high-calorie diets are at all events harmful to the renal (Rios et al., 2018). This is because high-calorie diets increase fat or carbohydrate intake. The accumulation of fat cells and their increased adiposity in tissues are the causes of obesity and are harmful to health (Braun, 2017).

The findings in Table (3) demonstrated a significant amount of vitamin D while C consumption was not significant between the 2 groups. Contradictory findings have been found in earlier research on the relationship between vitamin C intake and renal illness (Ferraro and Another, 2016; Farhadnejad and Colleagues 2016). The development of CKD stage three or above was linked to the increase in vitamin C consumption when compared to the recommended range. The current findings were indirectly supported by a previous study that linked excess vitamin C taking above the recommended threshold (90 mg/day) to a higher risk of renal gravels (Ferraro and Others 2016). Lamarche et al., (2011) reported that despite conflicting epidemiological data, a biologically plausible association exists between increased vitamin C intake and decreased eGFR. Patients with CKD should not take more than 100 mg of vitamin C daily due to the possibility that metabolic by-products of vitamin C could build up and impair renal function. reported that vitamin C's metabolites accumulate and impede the activity of the kidneys, patients with CKD shouldn't consume over one hundred mg/day of the vitamin.

In both groups, VD assimilation was decreased by 50% of RDI (Table 3). Kaur et al. (2019), said low VD consumption leads to endothelial dysfunction and inflammation. Gluba-Brzózka and Partner, (2018) found a high link between vitamin D therapy and improved outcomes in those on hemodialysis. Even in the initial phases of chronic renal disease, there is a deficit of vitamin D. According to experimental research low levels of VD have been linked to cardiac contractile failure, boosted heart mass, and raised myocardial collagen content.

Table (4) presents statistical data that demonstrates a major (P<0.05) variation in the phosphorus intake of each group. This table showed that the intake of iron and zinc was more than 50% from RDI and did not differ statistically between the two groups, as did the tables for other minerals. Intake of magnesium and potassium was less than 50% of RDI in
both groups. In contrast, sodium intake was higher in the sick and normal groups, respectively, than in the RDI (122.8 & 155.2%). In both groups, calcium intake was nearly fifty percent of RDI.

Due to decreased iron intake, increased metal losses, and poorer mobilization of iron from reserves, patients with CKD, especially those on dialysis, show substantial alterations in iron balance and tissue division (Wish and Teammate 2018). Iron homeostasis failure is a major cause of anemia in individuals with CKD if untreated. According to Kristensen et al., (2019), zinc is an essential mineral that controls the expression of several genes, including those related to antioxidant resistance, microglial immunity, and antiviral and antibacterial immunity.

A crucial mineral with catalytic, metabolic, and categorical functions is zinc. Deoxyribonucleic acid (DNA) replication, cell proliferation, energy consumption, and growth are among the enzyme-dependent processes in which zinc is engaged (Macdonald 2000; Haase and Rink 2014). Additionally, proteins' stability and structure depend on zinc (Laitaoja and Coworkers 2013). Maintaining the structure and makeup of cell membranes is also necessary (Maret, 2017). Recent research indicates that zinc also has a role in the regulation of leptin, insulin signaling, and antioxidant activity (Cheng and Chen, 2021; El-Adl et al., 2024).

Dietary phosphorus restriction is recommended as a technique for treating hyperphosphatemia because it has been associated with renal failure in individuals with CKD (Bellasi et al., 2011; Chang and Anderson 2017).

An increased dietary K+ consumption is a therapeutic challenge for patients with hyperkalemic-affected late-stage CKD (Palmer and Clegg 2016; Kovesdy et al., 2014). Dietary K+ restriction (3 g/d) is recommended for people who are at risk of hyperkalemia; however, it should only be used individually because it can prevent patients from benefiting from heart-healthy diets (Rastogi and Colleague workers 2016; Cupisti and another, 2018; Kinsella and Associate, 2010). However, it has been suggested that a high-potassium diet may be preventive against CKD because of its physiological effects, which include lowering blood pressure (BP) or acting as a vascular protectant (Wang et al., 2007). Patients with severe CKD should take up to 4700 mg of potassium per day, according to prior
One modifiable factor that can affect a patient's risk of both cardiovascular disease and the course of their CKD is their dietary sodium consumption. The impact of salt consumption on fluid overload and hypertension—two factors that are predictive of renal advancement and cardiovascular remodeling—has been shown in earlier studies. Furthermore, a high salt diet may harm blood arteries (Suckling et al., 2010; Gradual and Colleagues 2017; McMahon et al., 2013).

Notably significant (P<0.001) differences were observed in the studied biochemical parameters for assessing renal functions and eGFR between CKD patients with complicated CVD and the normal group (Table 5). Kidney and cardiovascular health are negatively impacted when uremic solutes are retained due to reduced kidney excretory function (Velasquez et al., 2018). The epithelial bonds that keep together luminal cells are weakened when gut bacteria convert urea to ammonia. According to Vaziri et al. (2013), this makes it possible for germs to enter the bloodstream and cause systemic inflammation, which may accelerate the onset of chronic kidney disease (CKD).

Contrasting group 2's cardiac parameters to those of the healthy category (G1), Table (6) shows a substantial (P<0.05) rise. even though VCAM-1 and LDH were within normal limits. Significant increases in VCAM levels (P<0.001) were observed in G2. In the patient population, elevated levels of cardiac activity-related markers (CK-MB, LDH, and troponin) signify myocardial damage. Increases in these values in serum point to modifications in the heart membrane's integrity and permeability. The increase in the proinflammatory VCAM-1 indicates that these changes in the membrane could be brought on by the inflammatory state. Neutrophils can move and translocate across the intercellular link due to modifications in the cytoskeleton of the cellular endothelium and increased vascular permeability (Van Wetering et al., 2003). The endothelium's integrity may be further jeopardized by the interaction between neutrophils and VCAM-1, which is considered to activate inflammatory cells and induce transcellular permeability pathways that change the glycocalyx of the endothelium by releasing proteinases.
Data shown in Table (7) show that the patient group (G2) had significantly higher blood levels of triglycerides, LDLC, VLDL-C, AI, and AC. Furthermore, when compared to the normal group, the HDL-C levels in (G2) were significantly lower. There were appreciable increases in the serum levels of LDL-C and AC value between the CKD + CVD group and the normal individuals. Serum cholesterol levels between the two groups showed significant differences as well, while they were still within the normal range.

One of the most prevalent side effects of a chronic kidney disorder is dyslipidemia, which typically occurs concurrently with declining kidney performance. It advances according to the CKD stage (Saini et al., 2022). Mikolasevic and Fellow workers (2017) indicated that hypertriglyceridemia, primarily caused by elevated lipoprotein triglyceride levels and prolonged triglyceride breakdown, is the most common lipid anomaly in patients with CKD. Hirano and Collaborators (2003) displayed that triglyceride levels are higher in individuals with CKD due to decreased breakdown of triglyceride-rich lipoproteins caused by elevated serum levels of a protein known as C (Apo C). Cardiovascular events have been linked to elevated triglycerides and decreased HDL-C in patients with CKD (Turak et al., 2016). In a similar vein, high levels of triglyceride-rich lipoproteins are associated with lipid profiles in individuals in the later stages of CKD (Lamprea-Montealegre et al., 2018). While LDL-c and atherosclerotic events correlate in the general population, in patients with end-stage renal disease (ESRD), LDL-c has a negative correlation and a flat or weakly positive correlation with mortality at levels below the average and above the average. Those with CKD and kidney transplant recipients benefit from lowering LDL-C, whereas dialysis patients do not (Ferro and Workmate 2019).

Latest scientific research, according to Zewinger et al. (2017), suggests that the vascular effects of HDL-c can vary depending on the condition and that the quality and composition of blood lipids, particularly triglyceride-rich lipoproteins, and HDL-c, are significantly altered as kidney damage progresses, favoring an atherogenic profile. Adverse endothelial effects from HDL-c may also be observed in children with CKD who do not yet have cardiovascular risk factors such as diabetes, smoking, hypertension, or
dyslipidemia (Shroff, and Others 2014); (Jankowski and Else 2021).

Table (8) data showed a significant decrease in group 2's serum vitamin D levels. VDBP was non-significant in the two groups. CKD impairs the kidneys' capacity to carry out specific endocrine functions appropriately. Vitamin D metabolism is known to be mostly regulated by the kidneys, which convert vitamin D into its active form, 1,25-dihydroxy-VD, or calcitriol. Among many other reasons, dietary restrictions and reduced sun exposure increase the risk of multifactorial VD insufficiency in individuals with CKD. It is now widely acknowledged that VD deficiency affects many people globally (González-Parra and Colleagues 2012; Jean et al., 2017).

A significant proportion of people with chronic kidney disease (CKD), accounting for about 80% of pre-dialysis patients, suffer from vitamin D insufficiency. This deficit usually starts early in the illness and worsens when the kidneys fail (Caravaca-Fontan et al., 2016; Cardoso and Pereira, 2019). The Kidney Disease Improving Global Outcomes (KDIGO) group recommends Vitamin D supplementation. However, the agents or best practices for regaining vitamin D levels are not specified. In individuals with CKD, this impairment is caused by multiple variables that impact its metabolism's synthesis, activation, and degradation stages. The strategy for vitamin D supplementation in CKD has changed as clinical knowledge of its significance has grown to guarantee sufficient availability. With advancing CKD stages and declining renal mass, the capacity to produce active 1,25 vitamin D decreases, leading to its deficiency. To address this, supplementation with calcitriol or its analogs becomes necessary to compensate for compromised production in later CKD stages (beyond Stage 3), enabling the fulfillment of classical hormonal functions (Williams et al., 2009).

In the current study, anomalies in Vitamin D Binding Protein (DBP) and renal vitamin D metabolism were noted in CKD patients. According to this study, there is a correlation between decreased phosphorus excretion and active vitamin D production and the increasing reduction in renal function. Additionally, poor vitamin D status in uremic patients can stem from factors such as decreased appetite, gastrointestinal issues, limited dietary intake due to restrictions (like low-protein and low-phosphate diets), and reduced sun exposure due to mobility limitations (Yoon et al., 2019). CKD
patients exhibit a diminished response to high-dose cholecalciferol supplementation due to impaired renal vitamin D hydroxylation, exacerbating the deficiency. Research by Del Valle et al., (2007) found that 84% of hemodialysis (HD) patients with vitamin D insufficiency lacked sufficient sun exposure.  

**CONCLUSION:**

This study's monitoring of dietary intake revealed that low nutrient intakes, such as those of fiber, potassium, magnesium, vitamin D, and C, as well as many high nutrient intakes such as those of protein, calories, fat, salt, and phosphorus, harmed the patient's CVD and CKD. For these patients, nutrition intervention is therefore essential. Novel biomarkers and metabolic pathways connected to CKD and CVD are potential targets for prognostication and customized treatment. The ultimate goal of lowering morbidity necessitates further investigation and creativity in this field to provide more effective therapy strategies and monitoring techniques.

**RECOMMENDATIONS:**

- Individualized Nutritional Interventions:
- Develop personalized nutrition plans for patients with CKD and CVD, ensuring a balanced intake of essential nutrients to mitigate negative impacts associated with their excesses or deficiencies.
- Regular Monitoring: Implement routine biochemical investigations to monitor key indicators for ills. This will help in early detection and timely management of disease progression.
- Education and Support: Provide comprehensive education and support programs for patients and caregivers about the importance of nutrition in managing CKD and CVD. This should include practical advice on dietary modifications and the potential impact of different nutrients on health.
- Research and Innovation: Continue research to identify and validate novel biomarkers and biochemical pathways associated with CKD and CVD. This will enhance prognostication and allow for more tailored treatment approaches. Promote innovation in therapeutic strategies and surveillance methods to improve the efficacy of interventions and reduce morbidity rates.
- Interdisciplinary Collaboration: Foster collaboration between nephrologists, cardiologists, dietitians, and other healthcare professionals to
ensure a comprehensive and integrated approach to patient care.

By implementing these recommendations, healthcare providers can enhance the quality of care for patients suffering from CKD and CVD, ultimately improving patient outcomes and quality of life.

REFERENCES

Aaron KJ and Sanders PW (2013):

American Heart Association (AHA). (2021):

Bellasi A; Mandreoli M; Baldrati L; Corradini M; Di Nicolò P; Malmusi G and Santoro A (2011):

Braun JM (2017):

Bucolo G and David H (1973):

Caravaca-Fontán F; Gonzales-Candia B; Luna E and Caravaca F (2016):

Cardoso MP and Pereira LAL (2019):
The Nutritional and Biochemical Indicators of Cardiovascular and Chronic Kidney Diseases Patients Compared to a Normal Group

Mona A. Mohamed; Nehad R Ibrahim; Amal H Emara; Entsar M. Ahmad; Fatma K. A. Hamid and Hanaa H El-Sayed


El-Adl M; Rezk S; Ali M; Lashen S; Fouda M; El Sebaei MG; Shukry M; Abdelkhalek N and Naiel MAE (2024): The efficiency of zinc sulfate immersion bath on improved

**Farhadnejad H.; Asghari G; Mirmiran P; Yuzbashian E and Azizi F (2016):**

**Ferraro PM; Curhan GC; Gambaro G and Taylor EN (2016):**

**Ferro CJ; Mark PB; Kanbay M; Sarafidis P; Heine GH; Rossignol P; Massy ZA; Mallamaci F; Valdivielso JM; Malyszko J; Verhaar MC; Ekart R; Vanholder R; London G; Ortiz A and Zoccali C (2019):**
Lipid management in patients with chronic kidney disease.

**Food and Drug Administration FDA (2020):**
Daily value on the new nutrition and supplement facts labels.

**Giannitsis E; Kurz K; Hallermayer K; Jarausch J; Jaffe AS and Katus HA (2010):**

**Global Burden of Disease (GBD) Study (2020).**

**Gluba-Brzózka A; Franczyk B; Ciałkowska-Rysz A; Olszewski R and Rysz J (2018):**
Impact of Vitamin D on the Cardiovascular System in Advanced Chronic Kidney Disease (CKD) and Dialysis

González-Parra E; Avila PJ; Mahillo-Fernández I; Lentisco C; Gracia C; Egido J and Ortiz, A (2012):

Graudal NA; Hubeck-Graudal T and Jurgens G (2017):
Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride. *Cochrane Database Syst Rev.* 09; 4: CD004022. doi: 10.1002/1465 1858.CD004022.pub4

Haase H and Rink L (2014):

Hirano T; Sakaue T and Misaki A (2003):
Very low-density lipoprotein-apoprotein CI is increased in diabetic nephropathy: comparison with apoprotein CIII. *Kidney Int.*; 63(6):2171–2177. doi:10.1046/j.1523-1755. 00019.x

Holick MF; Binkley NC; Bischoff-Ferrari HA; Gordon CM; Hanley DA; Heaney RP; Murad MH and Weaver CM (2024):

Jankowski J; Floege J; Fliser D; Böhme M and Marx N. (2021):
Cardiovascular Disease in Chronic Kidney Disease Pathophysiological Insights and Therapeutic Options. *Circulation*.; 16;143(11):1157-1172. doi: 10.1161/ CIRCULATIONAHA.120.050686.

Jean G; Souberbielle JC and Chazot C (2017):
Ikizler TA; Burrowes JD; Byham-Gray LD; Campbell KL; Carrero JJ; Chan W; Fouque D; Friedman AN; Ghaddar S; Goldstein-Fuchs DJ; Kaysen GA; Kopple JD; Teta D; Yee-Moon Wang A and Cuppari L (2021):


Kalantar-Zadeh K and Fouque D (2017):


Kaur G; Singh J and Kumar J (2019):


Kidney Disease, Improving Global Outcomes KDIGO (2012):


Kim J; Lee J; Kim KN; Oh KH; Ahn C; Lee J; Kang D and Park SK (2018):


Kim SM and Jung JY (2020):


Kinsella S; Moran S; Sullivan MO; Molloy MG and Eustace JA (2010):


Kovesdy CP (2014):


Kristensen JH; Basit S; Wohlfahrt J; Damholt MB and Boyd HA (2019):
Pre-eclampsia and risk of later kidney disease: nationwide cohort study. *BMJ*; 365: I1516. doi:10.1136/bmj.11516

**Laitaoja M; Valjakka J,** and **Janis J** (2013):  

**Lamarche J; Nair R; Peguero A** and **Courville C** (2011):  

**Lamprea-Montealegre JA; Mc Clelland RL** and **Grams M** (2018):  

**Levey AS; Greene T; Kusek J** and **Beck GJ** (2000):  

**MacDonald RS** (2000):  
The role of zinc in growth and cell proliferation. *J Nutr*; 130(5S Suppl.): 1500se8s. doi: 10.1093/jn/130.5.1500S.

**Maret W** (2017):  

**McMahon EJ; Bauer JD; Hawley CM; Isbel NM; Stowasser M** and **Johnson DW** (2013):  

**Mikolasevic I; Žutelija M; Mavrinac V** and **Orlic L** (2017):  

**Mills KT; Xu Y; Zhang W; Bundy JD; Chen CS; Kelly TN; Chen J** and **He J** (2015):  
A systematic analysis of worldwide population-based data on the global burden of chronic

Mozaffarian D; Afshin A; Benowitz NL; Bittner V; Daniels SR; Franch HA; Jacobs DR Jr; Kraus WE; Kris-Etherton PM; Krummel DA; Popkin BM; Whitsel LP and Zakai NA (2012):


Mougios V (2007)


National Kidney Foundation (NKF) (2024):


National Nutrition Institute NNI (2006):

Food Composition Tables, Cairo, A.R.E., 2006.

Palmer BF and Clegg DJ (2016):


Rastogi A; Arman F and Alipourfetrati S (2016):

New agents in the treatment of hyperkalemia: an opportunity to optimize the use of RAAS inhibitors for blood pressure control and organ protection in

Ríos Varo R (2018):
Influence of diet caloric content on phosphate metabolism and vascular calcification. http://hdl.handle.net/10396/17546

Saini M; Vamne A and Kumar V (2022):

Schoolwerth DA and Sica AC (2004):

Shroff R; Speer T; Colin S; Charakida M; Zewinger S; Staels B; Chinetti-Gbaguidi G; Hettrich I; Rohrer L; O’Neill F; McLoughlin E; Long D; Shanahan CM; Landmesser U; Fliser D and Deanfield JE (2014):

Stopic B; Medic-Brkic B; Savic-Vujovic K; Davidovic Z; Todorovic J and Dimkovic N (2022):

Suckling RJ, He FJ, and Macgregor GA (2010):

Tietz NW; Rinker AD and Shaw LM (1983).
International Federation of Clinical Chemistry (IFCC) methods for the measurement of catalytic concentration of enzymes Part 5. IFCC method
The Nutritional and Biochemical Indicators of Cardiovascular and Chronic Kidney Diseases Patients Compared to a Normal Group

Mona A. Mohamed; Nehad R Ibrahim; Amal H Emara; Entsar M. Ahmad; Fatma K. A. Hamid and Hanaa H El-Sayed


Trinder P (1969):

Turak O; Afşar B and Ozcan F. (2016):

Van Wetering S; van den Berk N and van Buul JD (2003):

Vaziri ND; Yuan J and Norris K. (2013):

Velasquez MT; Centron P; Barrows I; Dwivedi R and Raj DS (2018):

Wang T; Teng K; Liu Y; Shi W; Zhang J; Dong E; Zhang X; Tao Y and Zhong J (2019):

Wang W; Soltero L; Zhang P; Huang XR; Lan HY and Adrogue HJ (2007):
World Health Organization (WHO) (2021):

Williams S; Malatesta K and Norris K (2009):

Wish JB; Aronoff GR; Bacon BR; Brugnara C; Eckardt KU; Ganz T; Macdougall IC; Núñez J; Perahia AJ, and Wood JC (2018):

Yoon UA; Kim YC; Lee H; Kwon S; An JN; Kim DK; Kim YS; Lim CS; Lee JP and Kim H (2019):

Zewinger S; Kleber ME; Rohrer L; Lehmann M; Triem S; Jennings RT; Petrakis I; Dressel A; Lepper PM; Scharnagl H; Ritsch A; Thorand B; Heier M; Meisinger C; de Las Heras Gala T; Koenig W; Wagenpfeil S; Schwedhelm E; Böger RH; Laufs U; von Eckardstein A; Landmesser U; Lüscher TF; Fliser D; März W; Meinitzer A and Speer T (2017):
Table 1. Distribution of criteria of the sample, stages of CKD, proteinuria, and dialysis in the studied groups

<table>
<thead>
<tr>
<th>Parameters</th>
<th>G1 Normal group</th>
<th>G2 Patient group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Count</td>
<td>%</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>♂</td>
<td>10</td>
<td>33.3</td>
</tr>
<tr>
<td>♀</td>
<td>20</td>
<td>66.7</td>
</tr>
<tr>
<td>Age range</td>
<td>45-60</td>
<td></td>
</tr>
<tr>
<td>BMI Mean</td>
<td>24.8</td>
<td></td>
</tr>
<tr>
<td>CKD stages</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>3</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>4</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>5</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>Proteinuria</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ve</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>trace</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>Nil</td>
<td>30</td>
<td>100</td>
</tr>
<tr>
<td>Dialysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>No</td>
<td>30</td>
<td>100</td>
</tr>
</tbody>
</table>

BMI is calculated using the equation kg/m², where kg is an individual’s weight in kilograms and m² is the square of their height in meters. Underweight: BMI <18.5; Normal weight: BMI >18.5–24.9; Overweight: BMI =25–29.9; Obesity: BMI ≥ 30
Table 2. Distribution of both macronutrient intake /day (mean ± SE) and % from RDI calculated according to these values means in studied groups.

<table>
<thead>
<tr>
<th>Macronutrients</th>
<th>G1 normal group</th>
<th>G2 patient group</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calories/kcal</td>
<td>1446.7±97.3</td>
<td>1773.0±102.9*</td>
<td>0.000</td>
</tr>
<tr>
<td>% from RDI</td>
<td>72.3%</td>
<td>88.7%</td>
<td></td>
</tr>
<tr>
<td>Protein /g</td>
<td>70.2±5.2</td>
<td>72.6±6.5</td>
<td>0.38</td>
</tr>
<tr>
<td>RDI 2000 kcal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>% from RDI</td>
<td>140%</td>
<td>145%</td>
<td></td>
</tr>
<tr>
<td>Fat /g</td>
<td>59.5±5.6</td>
<td>60.7±5.8</td>
<td>0.33</td>
</tr>
<tr>
<td>RDI 78 g</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>% from RDI</td>
<td>76.3%</td>
<td>77.8%</td>
<td></td>
</tr>
<tr>
<td>Carb. /g</td>
<td>163.5±14.5</td>
<td>233.4±12.9*</td>
<td>0.002</td>
</tr>
<tr>
<td>RDI 275 g</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>% from RDI</td>
<td>59.5%</td>
<td>84.9</td>
<td></td>
</tr>
<tr>
<td>Fiber</td>
<td>8.9±1.5</td>
<td>9.2±1.2</td>
<td>0.77</td>
</tr>
<tr>
<td>RDI 28 g</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>% from RDI</td>
<td>31.8%</td>
<td>32.9%</td>
<td></td>
</tr>
</tbody>
</table>

*At P < 0.05, the mean difference is significant. RDI as stated by the FDA in 2020 75–100% of the RDIs are considered adequate consumption levels, while fewer than 50% of the RDIs are deemed insufficient intake levels.

Table 3. Distribution of Vitamins C and D intake /day (mean ± SE) and % from RDI calculated according to these values means in different studied groups.

<table>
<thead>
<tr>
<th>Vitamins</th>
<th>G1 normal group</th>
<th>G2 patient group</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin C mg/day</td>
<td>28.9±8.0</td>
<td>36.8±11.4</td>
<td>0.296</td>
</tr>
<tr>
<td>RDI 90 mg/day</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>% from RDI</td>
<td>32.1%</td>
<td>40.9%</td>
<td></td>
</tr>
<tr>
<td>Vitamin D IU/day</td>
<td>56.5±7.1</td>
<td>34.9±2.9*</td>
<td>0.004</td>
</tr>
<tr>
<td>RDI 800 IU/day</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>% from RDI</td>
<td>7.1%</td>
<td>4.4%</td>
<td></td>
</tr>
</tbody>
</table>

*The mean difference is Significant at P < 0.05. RDI according to FDA 2020 Intake levels of 75–100 percent of the RDIs are regarded as adequate, whereas levels of less than 50 percent of the RDIs are deemed insufficient.
Table 4. Distribution of minerals intake /day (mean ± SE) and percent from RDI calculated according to these values means in different studied groups.

<table>
<thead>
<tr>
<th>Minerals</th>
<th>G1 Normal group</th>
<th>G2 Patients' group</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>IRON (mg/day)</td>
<td>11.4±0.8</td>
<td>13.2±0.7</td>
<td>0.07</td>
</tr>
<tr>
<td>RDI</td>
<td>18.0 mg/day</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% of RDI</td>
<td>62.2%</td>
<td>73.3%</td>
<td></td>
</tr>
<tr>
<td>ZINC (mg/day)</td>
<td>8.5 ±0.6</td>
<td>9.5±0.5</td>
<td>0.168</td>
</tr>
<tr>
<td>RDI</td>
<td>11.0 mg/day</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% for RDI</td>
<td>77.3%</td>
<td>86.4%</td>
<td></td>
</tr>
<tr>
<td>CALCIUM (mg/day)</td>
<td>630.5±54.0</td>
<td>665.0±64.2</td>
<td>0.328</td>
</tr>
<tr>
<td>RDI</td>
<td>1300 mg/day</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% of RDI</td>
<td>48.5%</td>
<td>51.2%</td>
<td></td>
</tr>
<tr>
<td>PHOSPHORUS (mg/day)</td>
<td>765.7±53.2</td>
<td>958.7±87.9*</td>
<td>0.03</td>
</tr>
<tr>
<td>RDI</td>
<td>1250 mg/day</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% for RDI</td>
<td>61.2%</td>
<td>76.7%</td>
<td></td>
</tr>
<tr>
<td>MAGNESIUM (mg/day)</td>
<td>116.9±11.3</td>
<td>123.9±14.7</td>
<td>0.359</td>
</tr>
<tr>
<td>RDI</td>
<td>420 mg/day</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% from RDI</td>
<td>27.8%</td>
<td>29.5</td>
<td></td>
</tr>
<tr>
<td>POTASSIUM (mg/day)</td>
<td>1797.3±129.8</td>
<td>2038.1±140.3</td>
<td>0.121</td>
</tr>
<tr>
<td>RDI</td>
<td>4700 mg/day</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% of RDI</td>
<td>38.2%</td>
<td>43.4%</td>
<td></td>
</tr>
<tr>
<td>SODIUM (mg/day)</td>
<td>2824.7±274.5</td>
<td>3569.8±316.3</td>
<td>0.05</td>
</tr>
<tr>
<td>RDI</td>
<td>2300 mg/day</td>
<td></td>
<td></td>
</tr>
<tr>
<td>% from RDI</td>
<td>122.8%</td>
<td>155.2%</td>
<td></td>
</tr>
</tbody>
</table>

*The mean difference is Significant at P < 0.05. RDI according to FDA 202 Intake levels of 75-100 percent of the RDIs are regarded as adequate, whereas levels of less than 50 percent of the RDIs are deemed insufficient.

Table 5. Distribution of kidney function tests (mean ± SD), and eGFR% in all studied groups.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Normal range</th>
<th>G1 normal group</th>
<th>G2 patient group</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urea (mg/dl)</td>
<td>5 - 20</td>
<td>19.5±1.3</td>
<td>86.5±6.5*</td>
<td>0.000</td>
</tr>
<tr>
<td>Creatinine (mg/dl)</td>
<td>0.7 - 1.3</td>
<td>0.9±0.02</td>
<td>3.8±0.5*</td>
<td>0.000</td>
</tr>
<tr>
<td>Uric acid (mg/dl)</td>
<td>2.5 - 7.0</td>
<td>4.1±0.2</td>
<td>7.9±0.4*</td>
<td>0.00</td>
</tr>
<tr>
<td>eGFR %</td>
<td>&gt; 90</td>
<td>105.7±2.9</td>
<td>21.8±4.6*</td>
<td>0.000</td>
</tr>
</tbody>
</table>

eGFR = estimated Glomerular Filtration Rate. The mean difference is Significant at P < 0.05.
Table 6. Distribution of Serum levels of cardiac parameters CK-MB, troponin, LDH, and VCAM-1 (mean ± SD), in all studied groups.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Normal range</th>
<th>G1 normal group</th>
<th>G2 patient group</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CK MB (IU/L)</td>
<td>5 - 25</td>
<td>13.5±1.2</td>
<td>33±3.2*</td>
<td>0.000</td>
</tr>
<tr>
<td>Troponin (ng/mL)</td>
<td>0 - 0.04</td>
<td>0.03±0.01</td>
<td>0.5±0.1*</td>
<td>0.011</td>
</tr>
<tr>
<td>LDH (U/L)</td>
<td>140 - 280</td>
<td>98.9±4.2</td>
<td>190±4.4*</td>
<td>0.000</td>
</tr>
<tr>
<td>VCAM-1 (ng/mL)</td>
<td>449 - 1103</td>
<td>216.3±4.5</td>
<td>391.6±7.6*</td>
<td>0.000</td>
</tr>
</tbody>
</table>

*The mean difference is Significant at P < 0.05

Table 7. Distribution significance of serum Lipid profile Atherogenic indices (mean ± SD), in all studied groups.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Normal range</th>
<th>G1 normal group</th>
<th>G2 patient group</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Triglycerides (mg/dl)</td>
<td>&lt; 130</td>
<td>96.2±6.8</td>
<td>154.9±12.3*</td>
<td>0.000</td>
</tr>
<tr>
<td>Total Cholesterol (mg/dl)</td>
<td>&lt; 200</td>
<td>153.1±11.2</td>
<td>172.3±2.9*</td>
<td>0.023</td>
</tr>
<tr>
<td>HDL-c (mg/dl)</td>
<td>&gt; 60</td>
<td>44.6±6.3</td>
<td>35.7±10.9</td>
<td>0.001</td>
</tr>
<tr>
<td>LDL-c (mg/dl)</td>
<td>&lt; 100</td>
<td>86.17±40.74</td>
<td>108.2±24.4*</td>
<td>0.005</td>
</tr>
<tr>
<td>VLDL (mg/dl)</td>
<td>2 - 30</td>
<td>21.19±5.58</td>
<td>31.59±12.1*</td>
<td>0.001</td>
</tr>
<tr>
<td>Atherogenic Index</td>
<td>0.11-0.21</td>
<td>0.07±0.02</td>
<td>0.67±0.02*</td>
<td>0.000</td>
</tr>
<tr>
<td>Atherogenic coefficient</td>
<td>2.02</td>
<td>0.9±0.2</td>
<td>4.4±0.4*</td>
<td>0.000</td>
</tr>
</tbody>
</table>

*The mean difference is Significant at P < 0.05  SD: Standard deviation  HDL-c: High-density lipoprotein cholesterol. LDL-c: low-density lipoprotein cholesterol  VLDL-c: very low-density lipoprotein cholesterol

Table 8. Distribution of serum levels of vitamin D and vitamin D binding protein (DBP) (mean ± SD).

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Normal range</th>
<th>G1 normal group</th>
<th>G2 patient group</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin D (ng/ml)</td>
<td>30 - 50</td>
<td>53.4±6.5</td>
<td>38.7±2.4*</td>
<td>0.000</td>
</tr>
<tr>
<td>VDBP (mg/l)</td>
<td>200 - 600</td>
<td>214.0</td>
<td>216.5</td>
<td>0.334</td>
</tr>
</tbody>
</table>

DBP: Vitamin D binding protein  * the results are significant when (P<0.05)
The Nutritional and Biochemical Indicators of Cardiovascular and Chronic Kidney Diseases Patients Compared to a Normal Group

Mona A. Mohamed; Nehad R Ibrahim; Amal H Emara; Entsar M. Ahmad; Fatma K. A. Hamid and Hanaa H El-Sayed

The Nutritional and Biochemical Indicators of Cardiovascular and Chronic Kidney Diseases Patients Compared to a Normal Group

Mona A. Mohamed; Nehad R Ibrahim; Amal H Emara; Entsar M. Ahmad; Fatma K. A. Hamid and Hanaa H El-Sayed

Bulletin of the National Nutrition Institute of the Arab Republic of Egypt June 2024(63) 76